8 September 2011 in PLOS ONE
Carbon dioxide (CO2) therapy refers to the transcutaneous administration of CO2 for therapeutic purposes. This effect has been explained by an increase in the pressure of O2 in tissues known as the Bohr effect. However, there have been no reports investigating the oxygen dissociation of haemoglobin (Hb) during transcutaneous application of CO2 in vivo. In this study, we investigate whether the Bohr effect is caused by transcutaneous application of CO2 in human living body. We used a novel system for transcutaneous application of CO2 using pure CO2 gas, hydrogel, and a plastic adaptor. The validity of the CO2 hydrogel was confirmed in vitro using a measuring device for transcutaneous CO2 absorption using rat skin. Next, we measured the pH change in the human triceps surae muscle during transcutaneous application of CO2 using phosphorus-31 magnetic resonance spectroscopy (31P-MRS) in vivo. In addition, oxy- and deoxy-Hb concentrations were measured with near-infrared spectroscopy in the human arm with occulted blood flow to investigate O2 dissociation from Hb caused by transcutaneous application of CO2. The rat skin experiment showed that CO2 hydrogel enhanced CO2 gas permeation through the rat skin. The intracellular pH of the triceps surae muscle decreased significantly 10 min. after transcutaneous application of CO2. The NIRS data show the oxy-Hb concentration decreased significantly 4 min. after CO2 application, and deoxy-Hb concentration increased significantly 2 min. after CO2 application in the CO2-applied group compared to the control group. Oxy-Hb concentration significantly decreased while deoxy-Hb concentration significantly increased after transcutaneous CO2 application. Our novel transcutaneous CO2 application facilitated an O2 dissociation from Hb in the human body, thus providing evidence of the Bohr effect in vivo.
15 February 2012 in Journal of Tissue Engineering and Regenerative Medicine
Mesenchymal progenitor cells (MPCs) play a critical role in fracture healing. Increasing evidence suggests that circulating MPCs in peripheral blood are mobilized during fracture healing and may contribute to fracture repair. However, to date, there have been no reports comparing the number of circulating MPCs in arterial blood (AB) with that in venous blood (VB) after fracture. In this study, we investigated the numbers of MPCs in AB, VB and bone marrow (BM) after fracture in rabbits via the colony‐forming unit–fibroblasts (CFU‐Fs) assay, and clarified the time‐course change. After femoral fracture in one side, the number of BM‐MPCs in the contralateral femur increased from day 1 to day 7. Correspondingly, the number of circulating MPCs in AB and VB increased. The number of circulating MPCs in AB was highest at post‐fracture day 4, whereas that in VB was highest at post‐fracture day 1, with significant difference compared to the control. Circulating MPCs in AB and VB after fracture may serve as new cell sources for bone tissue engineering. As the peaks of the number of circulating MPCs in AB and VB after fracture were different, our findings may provide new insights about when to collect circulating MPCs after fracture and from which blood to obtain them. Copyright © 2012 John Wiley & Sons, Ltd.